Centene Corp Company Profile (NYSE:CNC)

Centene Corp trades on the New York Stock Exchange (NYSE) under the ticker symbol "CNC."

Centene Corp (NYSE:CNC) announced its quarterly earnings results on Tuesday, July, 25th. The company reported $1.59 earnings per share for the quarter, beating analysts' consensus estimates of $1.30 by $0.29. The firm earned $11.95 billion during the quarter, compared to analysts' expectations of $11.69 billion. Centene Corp had a net margin of 2.11% and a return on equity of 16.37%. Centene Corp's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.29 earnings per share. View Centene Corp's Earnings History.

Centene Corp is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Centene Corp.

Centene Corp updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share guidance of $4.70-5.06 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.79. The company issued revenue guidance of $46.4-47.2 billion, compared to the consensus revenue estimate of $46.82 billion.

18 brokerages have issued 1 year price targets for Centene Corp's shares. Their forecasts range from $64.00 to $105.00. On average, they expect Centene Corp's share price to reach $85.60 in the next twelve months. View Analyst Ratings for Centene Corp.

Here are some recent quotes from research analysts about Centene Corp stock:

• 1. According to Zacks Investment Research, "Year to date, Centene’s shares have outperformed the industry. The company’s strong and consistent performance is likely to have generated confidence among the investors. It has seen substantial inorganic growth in the last five years. The acquisition of Health Net in 2016 bolstered the company’s growth, expansion and asset base. Its solid financial position provides a major boost to its capital deployment initiatives. The company’s strong Managed care segment also contributes to its strong results. Its second-quarter 2017 earnings per share surpassed the Zacks Consensus Estimate and improved year over year on the back of higher revenues. However, it suffers from rising level of debt and increasing borrowing cost that keeps draining the bottom-line. Growing  acquisition related expenses also continue to bother." (8/4/2017)
• 2. Cantor Fitzgerald analysts commented, "This morning, CNC reported 2Q17 results. Revenue of $11.95 billion was slightly ahead of FactSet consensus. Adjusted EPS was $1.59 vs. our estimate of $1.25 and consensus of $1.30." (7/25/2017)
• 3. Leerink Swann analysts commented, "We reiterate our Market Perform rating on CNC while raising PT to $64 from $62 after the 4Q report and almost 6% move up yesterday." (2/9/2017)

Some companies that are related to Centene Corp include Hospira (HSP), BioMarin Pharmaceutical (BMRN), Smith & Nephew plc (SN), Omnicare (OCR), Valeant Pharmaceuticals Intl (VRX), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Health Net (HNT), Patheon NV (PTHN), Hill-Rom Holdings (HRC), NMC Health PLC (NMC), Catalent (CTLT), Akorn (AKRX), Cotiviti Holdings (COTV), WuXi PharmaTech (Cayman) (WX), Puma Biotechnology (PBYI), Indivior PLC (INDV) and Enerplus Corp (ERF).

Centene Corp's management team includes the folowing people:

• Michael F. Neidorff, Chairman of the Board, President, Chief Executive Officer
• Jeffrey A. Schwaneke CPA, Chief Financial Officer, Executive Vice President, Treasurer
• Keith H. Williamson, Executive Vice President, General Counsel, Secretary
• Christopher D. Bowers, Executive Vice President - Marketing
• Cynthia J. Brinkley, Executive Vice President - Global Corporate Development
• Jesse N. Hunter, Executive Vice President - Products
• Christopher R. Isaak, Senior Vice President, Corporate Controller and Chief Accounting Officer
• Mark J. Brooks, Senior Vice President, Chief Information Officer
• Christopher A. Koster, Senior Vice President - Corporate Services
• Orlando Ayala, Independent Director

Centene Corp's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.70%), BlackRock Inc. (7.74%), Capital World Investors (4.42%), State Street Corp (4.15%), Wells Fargo & Company MN (2.43%) and Ameriprise Financial Inc. (2.03%). Company insiders that own Centene Corp stock include Carol Goldman, Christopher D Bowers, Jeffrey A Schwaneke, Jesse N Hunter, Keith H Williamson, Kenneth Rone Baldwin, Mark J Brooks, Michael F Neidorff, Richard A Gephardt and Robert K Ditmore. View Institutional Ownership Trends for Centene Corp.

Centene Corp's stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., American Century Companies Inc., Schroder Investment Management Group, Neuberger Berman Group LLC, William Blair Investment Management LLC, Korea Investment CORP, FMR LLC and BNP Paribas Arbitrage SA. Company insiders that have sold Centene Corp stock in the last year include Carol Goldman, Christopher D Bowers, Jeffrey A Schwaneke, Jesse N Hunter, Keith H Williamson, Kenneth Rone Baldwin, Mark J Brooks, Michael F Neidorff, Richard A Gephardt and Robert K Ditmore. View Insider Buying and Selling for Centene Corp.

Centene Corp's stock was purchased by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., AJO LP, Vanguard Group Inc., Numeric Investors LLC, Wedge Capital Management L L P NC, Wells Fargo & Company MN, Teachers Advisors LLC and HealthCor Management L.P.. View Insider Buying and Selling for Centene Corp.

Shares of Centene Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Centene Corp stock can currently be purchased for approximately $83.49.